Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
J Med Virol ; 95(4): e28735, 2023 04.
Artículo en Inglés | MEDLINE | ID: covidwho-2306536

RESUMEN

Data on the safety of inactivated COVID-19 vaccines in pregnant women is limited and monitoring pregnancy outcomes is required. We aimed to examine whether vaccination with inactivated COVID-19 vaccines before conception was associated with pregnancy complications or adverse birth outcomes. We conducted a birth cohort study in Shanghai, China. A total of 7000 healthy pregnant women were enrolled, of whom 5848 were followed up through delivery. Vaccine administration information was obtained from electronic vaccination records. Relative risks (RRs) of gestational diabetes mellitus (GDM), hypertensive disorders in pregnancy (HDP), intrahepatic cholestasis of pregnancy (ICP), preterm birth (PTB), low birth weight (LBW), and macrosomia associated with COVID-19 vaccination were estimated by multivariable-adjusted log-binomial analysis. After exclusion, 5457 participants were included in the final analysis, of whom 2668 (48.9%) received at least two doses of an inactivated vaccine before conception. Compared with unvaccinated women, there was no significant increase in the risks of GDM (RR = 0.80, 95% confidence interval [CI], 0.69, 0.93), HDP (RR = 0.88, 95% CI, 0.70, 1.11), or ICP (RR = 1.61, 95% CI, 0.95, 2.72) in vaccinated women. Similarly, vaccination was not significantly associated with any increased risks of PTB (RR = 0.84, 95% CI, 0.67, 1.04), LBW (RR = 0.85, 95% CI, 0.66, 1.11), or macrosomia (RR = 1.10, 95% CI, 0.86, 1.42). The observed associations remained in all sensitivity analyses. Our findings suggested that vaccination with inactivated COVID-19 vaccines was not significantly associated with an increased risk of pregnancy complications or adverse birth outcomes.


Asunto(s)
COVID-19 , Complicaciones del Embarazo , Nacimiento Prematuro , Embarazo , Recién Nacido , Femenino , Humanos , Estudios de Cohortes , Vacunas contra la COVID-19/efectos adversos , Mujeres Embarazadas , Macrosomía Fetal , Nacimiento Prematuro/epidemiología , Pueblos del Este de Asia , China/epidemiología , COVID-19/prevención & control , Resultado del Embarazo
3.
J Med Virol ; 2022 Oct 19.
Artículo en Inglés | MEDLINE | ID: covidwho-2237585

RESUMEN

Despite the high vaccination coverage, potential COVID-19 vaccine-induced adverse effects, especially in pregnant women, have not been fully characterized. We examined the association between COVID-19 vaccination before conception and maternal thyroid function during early pregnancy. We conducted a retrospective cohort study in Shanghai, China. A total of 6979 pregnant women were included. Vaccine administration was obtained from electronic vaccination records. Serum levels of thyroid hormone were measured by fluorescence and chemiluminescence immunoassays. Among the 6979 included pregnant women, 3470 (49.7%) received at least two doses of an inactivated vaccine. COVID-19 vaccination had a statistically significant association with both maternal serum levels of free thyroxine (FT4) and thyroid stimulating hormone (TSH). Compared with unvaccinated pregnant women, the mean FT4 levels were lower in pregnant women who had been vaccinated within 3 months before the date of conception by 0.27 pmol/L (ß = -0.27, 95% confidence interval [CI], -0.42, -0.12), and the mean TSH levels were higher by 0.08 mIU/L (ß = 0.08, 95% CI, 0.00, 0.15). However, when the interval from vaccination to conception was prolonged to more than 3 months, COVID-19 vaccination was not associated with serum FT4 or TSH levels. Moreover, we found that COVID-19 vaccination did not significantly associate with maternal hypothyroidism. Our study suggested that vaccination with inactivated COVID-19 vaccines before conception might result in a small change in maternal thyroid function, but this did not reach clinically significant levels.

5.
China Geology ; 5(3):402-410, 2022.
Artículo en Inglés | PMC | ID: covidwho-2044359

RESUMEN

This study investigated water samples collected from the surface water and groundwater in Wuhan City, Hubei Province, China in different stages of the outbreak of the coronavirus disease 2019 (hereinafter referred to as COVID-19) in the city, aiming to determine the distribution characteristics of antiviral drugs in the city’s waters. The results are as follows. The main hydrochemical type of surface water and groundwater in Wuhan was Ca-HCO3. The major chemical components in the groundwater had higher concentrations and spatial variability than those in the surface water. Two antiviral drugs and two glucocorticoids were detected in the surface water, groundwater, and sewage during the COVID-19 outbreak. Among them, chloroquine phosphate and cortisone had higher detection rates of 32.26% and 25.80%, respectively in all samples. The concentrations of residual drugs in East Lake were higher than those in other waters. The main drug detected in the waters in the later stage of the COVID-19 outbreak in Wuhan was chloroquine phosphate, whose detection rates in the surface water and the groundwater were 53.85% and 28.57%, respectively. Moreover, the detection rate and concentration of chloroquine phosphate were higher in East Lake than in Huangjia Lake. The groundwater containing chloroquine phosphate was mainly distributed along the river areas where the groundwater was highly vulnerable. The residual drugs in the surface water and the groundwater had lower concentrations in the late stage of the COVID-19 outbreak than in the middle of the outbreak, and they have not yet caused any negative impacts on the ecological environment.©2022 China Geology Editorial Office.

6.
Emerg Microbes Infect ; 11(1): 2222-2228, 2022 Dec.
Artículo en Inglés | MEDLINE | ID: covidwho-1997030

RESUMEN

ABSTRACTMulticenter case series has reported patients with hepatic injury following COVID-19 vaccination, which raised concern for the possibility of vaccine-induced liver dysfunction. We aimed to assess the impact of COVID-19 vaccination on liver function of pregnant women, who may be uniquely susceptible to vaccine-induced liver dysfunction. We conducted a retrospective cohort study at a tertiary hospital in Shanghai, China. Vaccine administration was obtained from the electronic vaccination record. Serum levels of alanine transaminase (ALT), aspartate transaminase (AST), total bile acid (TBA) and total bilirubin (TBIL) in early pregnancy were determined by enzymatic methods. Among the 7745 included pregnant women, 3832 (49.5%) received at least two doses of an inactivated vaccine. COVID-19 vaccination was significantly associated with higher levels of maternal serum TBA. Compared with unvaccinated pregnant women, the mean TBA levels increased by 0.17 µmol/L (ß = 0.17, 95% CI, 0.04, 0.31) for women who had been vaccinated within 3 months before the date of conception. Moreover, COVID-19 vaccination was significantly associated with an increased risk of maternal hyperbileacidemia. The risk of hyperbileacidemia increased by 113% (RR = 2.13; 95% CI, 1.17-3.87) for pregnant women who had been vaccinated within 3 months before conception compared with unvaccinated pregnant women. However, when the interval from complete vaccination to conception was prolonged to more than 3 months, COVID-19 vaccination was not associated with serum TBA levels or maternal hyperbileacidemia. Our findings suggest that vaccination with inactivated COVID-19 vaccines more than 3 months before conception have no detrimental effects on maternal liver function in early pregnancy.


Asunto(s)
Vacunas contra la COVID-19 , COVID-19 , Mujeres Embarazadas , Alanina Transaminasa , Aspartato Aminotransferasas , Ácidos y Sales Biliares , Bilirrubina , COVID-19/prevención & control , Vacunas contra la COVID-19/efectos adversos , China/epidemiología , Estudios de Cohortes , Femenino , Humanos , Hígado , Pruebas de Función Hepática , Embarazo , Estudios Retrospectivos , Vacunas de Productos Inactivados
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA